BR112021025172A2 - Proteínas de fusão para vacinas de tuberculose - Google Patents

Proteínas de fusão para vacinas de tuberculose

Info

Publication number
BR112021025172A2
BR112021025172A2 BR112021025172A BR112021025172A BR112021025172A2 BR 112021025172 A2 BR112021025172 A2 BR 112021025172A2 BR 112021025172 A BR112021025172 A BR 112021025172A BR 112021025172 A BR112021025172 A BR 112021025172A BR 112021025172 A2 BR112021025172 A2 BR 112021025172A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
tuberculosis
relates
present
vaccines
Prior art date
Application number
BR112021025172A
Other languages
English (en)
Inventor
Claus Aagaard
Lawætz Andersen Peter
Rasmus Mortensen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Publication of BR112021025172A2 publication Critical patent/BR112021025172A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteínas de fusão para vacinas de tuberculose. a presente invenção refere-se a proteínas de fusão baseadas em polipeptídeos antigênicos de mycobacterium tuberculosis para prevenir, inibir ou tratar infecções e/ou doenças causadas por uma espécie do complexo da tuberculose. em particular, a presente invenção refere-se a proteínas de fusão que compreendem antígenos que não iniciam uma resposta imunológica contra bcg e/ou repetições de esat-6. as proteínas de fusão podem compreender uma combinação de antígenos precoces e tardios. além disso, a presente invenção refere-se a vacinas, composições imunogênicas e composições farmacêuticas que compreendem as proteínas de fusão.
BR112021025172A 2019-06-14 2020-06-12 Proteínas de fusão para vacinas de tuberculose BR112021025172A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19180280 2019-06-14
PCT/EP2020/066343 WO2020249756A1 (en) 2019-06-14 2020-06-12 Fusion proteins for tuberculosis vaccines

Publications (1)

Publication Number Publication Date
BR112021025172A2 true BR112021025172A2 (pt) 2022-01-25

Family

ID=66999556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025172A BR112021025172A2 (pt) 2019-06-14 2020-06-12 Proteínas de fusão para vacinas de tuberculose

Country Status (5)

Country Link
EP (1) EP3983011A1 (pt)
KR (1) KR20220032054A (pt)
CN (1) CN114222762A (pt)
BR (1) BR112021025172A2 (pt)
WO (1) WO2020249756A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112852848B (zh) * 2021-03-17 2022-04-29 中国农业大学 一种含密码子优化的结核分枝杆菌融合蛋白ah疫苗
KR102666314B1 (ko) * 2021-05-18 2024-05-16 한양대학교 에리카산학협력단 Mpt63 및 mpt64 유래 재조합 mpt 단백질 및 이의 용도
CN116769056A (zh) * 2023-07-07 2023-09-19 武汉大学 融合蛋白及纯化制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248084B (zh) * 2005-06-23 2013-11-06 国家血清研究中心 包含潜伏感染阶段期间所表达的抗原的结核疫苗
ES2647070T3 (es) 2005-06-23 2017-12-19 Statens Serum Institut Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
JP5981138B2 (ja) * 2008-07-25 2016-08-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP6333814B2 (ja) * 2012-07-10 2018-05-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． マイコバクテリア抗原ワクチン
JP6470179B2 (ja) * 2012-10-23 2019-02-13 スタテンス セールム インスティトゥート 結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
CN106232138A (zh) * 2014-04-24 2016-12-14 国家血清研究所 新型结核分枝杆菌疫苗

Also Published As

Publication number Publication date
CN114222762A (zh) 2022-03-22
EP3983011A1 (en) 2022-04-20
KR20220032054A (ko) 2022-03-15
WO2020249756A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
EA201890355A1 (ru) Новые способы индукции иммунного ответа
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112019008844A2 (pt) conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs
BR112015004593A2 (pt) composições imunogênicas
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
HRP20180039T1 (hr) Antigeni pseudomonasa i kombinacije antigena
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
BR112018071965A2 (pt) tratamento da dermatite atópica canina
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
BR112018005581A2 (pt) peptídeo derivado de foxm1 e vacina incluindo o mesmo